Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E8LA
|
|||
| Drug Name |
Saroglitazar
|
|||
| Synonyms |
Lipaglyn; 495399-09-2; UNII-E0YMX3S4JD; E0YMX3S4JD; Saroglitazar magnesium; (S)-2-Ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid; Saroglitazar [INN]; saroglitazarum; SCHEMBL16346340; DTXSID10197819; MRWFZSLZNUJVQW-DEOSSOPVSA-N; CHEBI:134708; AKOS027337115; CS-6149; DB13115; HY-19937; (2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid; (S)-alpha-ethoxy-4-[2-[-methyl-5-[4-(methylthio) phenyl]-1H-pyrrol-1-yl]ethox
Click to Show/Hide
|
|||
| Indication | Dyslipidemia [ICD-11: 5C80-5C81] | Approved | [1] | |
| Company |
Zydus Cadila Gujarat, India
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H29NO4S
|
|||
| Canonical SMILES |
CCOC(CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O
|
|||
| InChI |
1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1
|
|||
| InChIKey |
MRWFZSLZNUJVQW-DEOSSOPVSA-N
|
|||
| CAS Number |
CAS 495399-09-2
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:134708
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020 Dec 3;10(1):21117. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.